The discovery and development of omalizumab for the treatment of asthma

Expert Opinion on Drug Discovery

Volumn 10, Issue 9, 2015, Pages 1033-1042

  Licari, Amelia ^a   Marseglia, Gianluigi ^a   Castagnoli, Riccardo ^a   Marseglia, Alessia ^a   Ciprandi, Giorgio ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

allergic asthma; anti IgE therapy; omalizumab

Indexed keywords

IMMUNOGLOBULIN E; OMALIZUMAB; ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT;

ALLERGIC ASTHMA; ANAPHYLAXIS; ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG IDENTIFICATION; DRUG INDUCED HEADACHE; DRUG MARKETING; DRUG SAFETY; HUMAN; INFLAMMATORY CELL; LUNG FUNCTION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; SERUM SICKNESS; SINUSITIS; SYSTEMATIC REVIEW (TOPIC); TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URTICARIA; ADOLESCENT; ADULT; ANIMAL; ASTHMA; CHILD; IMMUNOLOGY;

ADOLESCENT; ADULT; ANIMALS; ANTI-ALLERGIC AGENTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; HUMANS; IMMUNOGLOBULIN E; OMALIZUMAB;

EID: 84938923215     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2015.1048220     Document Type: Review

References (68)

1. Ishizaka K, Ishizaka T, Hornbrook MM. Physico-chemical properties of human reaginic antibody. IV. Presence of a unique immunoglobulin as a carrier of reaginic activity. J Immunol 1966; 97: 75-85
2. Stanworth DR. The discovery of IgE. Allergy 1993; 48: 67-71
3. Holgate ST. New strategies with anti-IgE in allergic diseases. World Allergy Organ J 2014; 7: 17
4. Broide DH. Molecular and cellular mechanisms of allergic disease. J Allergy Clin Immunol 2001; 108: S65-71
5. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). 2014. Available from: http://www.ginasthma.org/local/uploads/files/GINA-Report-2014-Jun11.pdf
6. Novak N, Bieber T. Allergic and nonallergic forms of atopic diseases. J Allergy Clin Immunol 2003; 112: 252-62
7. Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014; 43: 343-73
8. Chang TW. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 2000; 18: 157-62
9. Holgate S, Casale T, Wenzel S, et al. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005; 115: 459-65
10. Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 2014; 1: CD003559
11. Hook WA, Berenstein E, Basciano LA, et al. Monoclonal antibodies to human IgE. Fed Proc 1981; 40: 968(A4177)
12. Baniyash M, Eshhar Z. Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE. Eur J Immunol 1984; 14: 799-807
13. Baniyash M, Kehry M, Eshhar Z. Anti-lgE monoclonal antibodies directed at the Fc receptor binding site. Mol Immuno1 1988; 25: 705-11
14. Heusser CH, Bews J, Brinkmann V, et al. New concepts of IgE regulation. Int Arch Allergy Appl Immunol 1991; 94: 87-90
15. Heusser C, Jardieu P. Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 1997; 9: 805-13
16. Morrison SL, Johnson M J, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 1984; 81: 6851-5
17. Reichmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988; 332: 323-7
18. Logsdon SL, Oettgen HC. Anti-IgE Therapy: Clinical Utility and Mechanistic Insights. Curr Top Microbiol Immunol 2015; 388: 39-61
19. Presta LG, Lahr SJ, Shields RL, et al. Humanization of an antibody directed against IgE. J Immunol 1993; 151: 2623-32
20. Haak-Frendscho M, Robbins K, et al. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 1994; 82: 306-13
21. Corne J, Djukanovic R, Thomas L, et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics. J Clin Invest 1997; 99: 879-87
22. Holgate ST, Djukanović R, Casale T, Bousquet J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin Exp Allergy 2005; 35: 408-16
23. MacGlashan D. Loss of receptors and IgE in vivo during treatment with anti-IgE antibody. J Allergy Clin Immunol 2004; 114: 1472-4
24. Beck LA, Marcotte GV, MacGlashan D, et al. Omalizumab-induced reductions in mast cell Fce psilon RI expression and function. J Allergy Clin Immunol 2004; 114: 527-30
25. Prussin C, Griffith DT, Boesel KM, et al. Omalizumab treatment downregulates dendritic cell FcepsilonRI expression. J Allergy Clin Immunol 2003; 112: 1147-54
26. Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol 2010; 125: 896-901.e6
27. Pelaia G, Gallelli L, Renda T, et al. Update on optimal use of omalizumab in management of asthma. J Asthma Allergy 2011; 4: 49-59
28. Food and Drug Administration. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/103976s5211lbl.pdf
29. Liu J, Lester P, Builder S, Shire SJ. Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. Biochemistry 1995; 34: 10474-82
30. Fox JA, Hotaling TE, Struble C, et al. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J Pharmacol Exp Ther 1996; 279: 1000-8
31. Fahy JV, Fleming HE, Wong HH, et al. The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 1997; 155: 1828-34
32. Boulet LP, Chapman KR, Côté J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 1997; 155: 1835-40
33. Milgrom H, Fick RB Jr, Su JQ, et al. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N Engl J Med 1999; 341: 1966-73
34. Casale T, Racine A, Sallas W, et al. Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 105: S357
35. Aderoth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2000; 106: 253-9
36. Solèr M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001; 18: 254-61
37. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001; 108: 184-90
38. Milgrom H, Berger W, Nayak A, et al. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). Pediatrics 2001; 108 (2): E36
39. Lemanske RF Jr, Nayak A, McAlary M, et al. Omalizumab improves asthma-related quality of life in children with allergic asthma. Pediatrics 2002; 110 (5): e55
40. Licari A, Marseglia A, Caimmi S, et al. Omalizumab in children. Paediatr Drugs 2014; 16: 491-502
41. Lanier B, Bridges T, Kulus M, et al. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma. J Allergy Clin Immunol 2009; 124: 1210-16
42. Milgrom H, Fowler-Taylor A, Vidaurre CF, Jayawardene S. Safety and tolerability of omalizumab in children with allergic (IgE-mediated) asthma. Curr Med Res Opin 2011; 27: 163-9
43. Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. N Engl J Med 2011; 364: 1005-15
44. Brusselle G, Michils A, Louis R, et al. "Real-life" effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study. Respir Med 2009; 103: 1633-42
45. Schumann C, Kropf C, Wibmer T, et al. Omalizumab in patients with severe asthma: the XCLUSIVE study. Clin Respir J 2012; 6: 215-27
46. Braunstahl GJ, Chen CW, Maykut R, et al. The eXpeRience registry: the real-world effectiveness of omalizumab in allergic asthma. Respir Med 2013; 107: 1141-51
47. Deschildre A, Marguet C, Salleron J, et al. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey. Eur Respir J 2013; 42: 1224-33
48. Rodrigo GJ, Neffen H, Castro-Rodriguez JA. Efficacy and safety of subcutaneous omalizumab vs placebo as add-on therapy to corticosteroids for children and adults with asthma: a systematic review. Chest 2011; 139: 28-35
49. Corren J, Casale TB, Lanier B, et al. Safety and tolerability of omalizumab. Clin Exp Allergy 2009; 39: 788-97
50. Busse W, Buhl R, Fernandez Vidaurre C, et al. Omalizumab and the risk of malignancy: results from a pooled analysis. J Allergy Clin Immunol 2012; 129: 983-9.e6
51. Long A, Rahmaoui A, Rothman KJ, et al. Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab. J Allergy Clin Immunol 2014; 134: 560-567.e4
52. Li J, Goulding M, Seymour S, Starke P. EXCELS study results do not rule out potential cancer risk with omalizumab. J Allergy Clin Immunol 2015; 135: 289
53. FDA Drug Safety Communication. FDA approves label changes for asthma drug Xolair (omalizumab), including describing slightly higher risk of heart and brain adverse events. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm414911.htm
54. Oba Y, Salzman GA. Cost-effectiveness analysis of omalizumab in adults and adolescents with moderate-to-severe allergic asthma. J Allergy Clin Immunol 2004; 114: 265-9
55. Domínguez-Ortega J, Phillips-Anglés E, Barranco P, Quirce S. Cost-effectiveness of asthma therapy: a comprehensive review. J Asthma 2015; 1
56. Costello RW, Long DA, Gaine S, et al. Therapy with omalizumab for patients with severe allergic asthma improves asthma control and reduces overall healthcare costs. Ir J Med Sci 2011; 180: 637-41
57. Menzella F, Facciolongo N, Piro R, et al. Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up. Ther Adv Respir Dis 2012; 6: 87-95
58. van Nooten F, Stern S, Braunstahl GJ, et al. Cost-effectiveness of omalizumab for uncontrolled allergic asthma in the Netherlands. J Med Econ 2013; 16: 342-8
59. Norman G, Faria R, Paton F, et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technol Assess 2013; 17: 1-342
60. McKeage K. Omalizumab: a review of its use in patients with severe persistent allergic asthma. Drugs 2013; 73: 1197-212
61. Lowe PJ, Renard D. Omalizumab decreases IgE production in patients with allergic (IgE-mediated) asthma; PKPD analysis of a biomarker, total IgE. Br J Clin Pharmacol 2011; 72: 306-20
62. Nopp A, Johansson SG, Adédoyin J, et al. After 6 years with Xolair; a 3-year withdrawal follow-up. Allergy 2010; 65: 56-60
63. Roth M, Zhong J, Zumkeller C, et al. The role of IgE-receptors in IgE-dependent airway smooth muscle cell remodelling. PLoS One 2013; 8: e56015
64. Riccio AM, Dal Negro RW, Micheletto C, et al. Omalizumab modulates bronchial reticular basement membrane thickness and eosinophil infiltration in severe persistent allergic asthma patients. Int J Immunopathol Pharmacol 2012; 25: 475-84
65. Bousquet J, Rabe K, Humbert M, et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir Med 2007; 101: 1483-92
66. Busse W, Spector S, Rosén K, et al. High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. J Allergy Clin Immunol 2013; 132: 485-6.e11
67. Hanania NA, Wenzel S, Rosén K, et al. Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 2013; 187: 804-11
68. Mauri P, Riccio AM, Rossi R, et al. Proteomics of bronchial biopsies: galectin-3 as a predictive biomarker of airway remodelling modulation in omalizumab-treated severe asthma patients. Immunol Lett 2014; 162: 2-10